I believe Spain is moving towards that as is France, Sweden. And as those bans come in place, it creates a lot more sort of propitious marketplace for us. So the product is doing well where we have reimbursements, Sweden and the UK and reimbursement is beginning to get traction alongside the smoking bans.

Seamus Fernandez (Leerink Swann): Do you have an overall view into your business that characterizes the impact of an economic environment in tier-3 access?

Ian Read: Our data shows that as tier-3 or even of they are on tier 2 and co-pays increase. It is not positive for scripts or scripts being filled. So, that would indicate that we would see a more difficult environment. But on the other hand, you have these positive impacts of Part D and in government programs.

Steve Scala (Cowen & Co): Are your reps out talking about ENHANCE and perhaps drawing parallels to the REVERSAL study?

Jeffrey Kindler: Our reps are out there promoting the advantages of Lipitor in the data that supports it. And we feel very strongly that that is the best way to position Lipitor, and they are out there doing that even as we speak.